FindTrial
Sign In

Significance of Factor Ba in Pediatric Post-HSCT TA-TMA Prevention

Factor Ba Dynamic Monitoring to Boost Pediatric Post-HSCT TA-TMA Prevention and Treatment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113244
Enrollment
Unknown
Registered
2025-11-26
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transplant-Associated Thrombotic Microangiopathy

Interventions

TA-TMA group:None
non TA-TMA group:None

Sponsors

Wuhan Childrens Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age <= 18 years ; 2. Underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Wuhan Children’s Hospital; 3. Retrospective cohort: Children who received transplantation between January 2024 and April 2025; 4. Prospective cohort: Children who receive transplantation after July 2025 (informed consent form must be signed).

Exclusion criteria

Exclusion criteria: 1. Patients who underwent autologous hematopoietic stem cell transplantation (auto-HSCT); 2. Patients with incomplete clinical data or substandard sample quality; 3. Patients who did not sign the informed consent form in the prospective study.

Design outcomes

Primary

MeasureTime frame
Factor Ba;sC5b-9;—

Secondary

MeasureTime frame
complete blood count;peripheral blood cell morphology;serum renal function;lactate dehydrogenase;—

Countries

China

Contacts

Public ContactZhang Lannan

Wuhan Childrens Hospital

zhanglannan63@163.com+86 27 82433402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026